v3.26.1
Summary of Significant Accounting Policies - Summary of Selected Financial Information with Respect to Operating Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]            
License revenue         $ 20,000  
Direct external research and development expenses by program:            
MZE829 $ 8,444   $ 5,199   15,540 $ 9,823
MZE782 3,177   4,582   8,471 8,948
Discovery research and other programs 3,596   2,742   6,641 5,752
Internal research and development expenses:            
Personnel-related 14,875   10,609   28,866 20,953
Facilities, lab supplies and other 4,848   4,976   9,570 10,212
Total research and development expenses 34,940   28,108   69,088 55,688
General and administrative expenses 13,095   8,366   25,500 16,187
Total operating expenses 48,035   36,474   94,588 71,875
Loss from operations (48,035)   (36,474)   (74,588) (71,875)
Segment other income, net 3,308   2,795   5,653 5,410
Net loss $ (44,727) $ (24,208) $ (33,679) $ (32,786) $ (68,935) $ (66,465)